Biogen traded at $206.26 this Friday July 1st, increasing $2.32 or 1.14 percent since the previous trading session. Looking back, over the last four weeks, Biogen gained 3.90 percent. Over the last 12 months, its price fell by 40.85 percent. Looking ahead, we forecast Biogen to be priced at 206.23 by the end of this quarter and at 190.03 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
206.26
Daily Change
1.14%
Yearly
-40.85%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 152.11 -1.05 -0.69% 32.07%
Acadia Pharmaceuticals 14.27 0.18 1.28% -41.28%
Acorda Therapeutics 0.47 0.004 0.86% -89.58%
ALKERMES 29.95 0.16 0.54% 18.38%
Amgen 242.55 -0.75 -0.31% -2.47%
Bayer 57.35 0.63 1.11% 11.42%
Biogen 206.26 2.32 1.14% -40.85%
Bluebird Bio 4.25 0.11 2.63% -86.89%
BioMarin Pharmaceutical 83.46 0.59 0.71% -0.54%
Bristol-Myers Squibb 75.81 -1.19 -1.55% 13.23%
Esperion Therapeutics 6.31 -0.05 -0.79% -69.20%
Gilead Sciences 61.63 -0.18 -0.29% -11.07%
Intercept Pharmaceuticals 13.92 0.11 0.80% -30.37%
Incyte Corp 76.81 0.84 1.11% -8.10%
Intra Cellular Therapies 55.19 -1.89 -3.31% 30.63%
Eli Lilly 319.70 -4.53 -1.40% 36.65%
Merck & Co 90.88 -0.29 -0.32% 15.62%
Moderna Inc 150.17 7.32 5.12% -35.91%
Marinus Pharmaceuticals 4.90 0.06 1.24% -73.99%
Neurocrine Biosciences 98.67 1.19 1.22% 0.06%
Novartis 80.21 -0.64 -0.79% -5.10%
Puma Biotechnology 2.80 -0.05 -1.75% -68.25%
Pfizer 51.49 -0.94 -1.79% 29.60%
PTC Therapeutics 41.38 1.32 3.30% -3.97%
Ultragenyx Pharmaceutical 62.63 2.97 4.98% -33.52%
Regeneron Pharmaceuticals 588.96 -2.17 -0.37% 0.91%
Sanofi 97.52 1.18 1.22% 10.94%
Seattle Genetics 179.11 2.17 1.23% 13.89%
Sangamo BioSciences 4.19 0.05 1.21% -64.22%
Sanofi 50.68 0.65 1.30% -3.23%
Sarepta Therapeutics 75.68 0.72 0.96% 0.58%
Teva Pharmaceutical Industries Ltd 2,670.00 -83.00 -3.01% -18.10%
United Therapeutics 235.05 -0.59 -0.25% 27.52%
Vertex Pharmaceuticals 282.69 0.90 0.32% 40.96%

Indexes Price Day Year
US500 3778 -7.19 -0.19% -13.19%
USND 10999 -29.50 -0.27% -24.87%
USNDX 11463 -40.90 -0.36% -22.17%

Biogen
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.